Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Protective Efficacy of a Vaccine Derived From the Synthetic CS Protein of Plasmodium Vivax

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Naïve group~Healthy men and women aged 18-45 years. Signing freely and voluntary informed consent , accompanied by two witnesses who also sign.~Not have a history of malaria infection. For women, use of adequate contraception from the star restriction to be lifted by a doctor for contraception study. Accept not to travel to areas considered endemic for malaria during Trophies infectious period (1 month ) ( Buenaventura , Tierralta , Pretoria , Tumaco ,Urabá and Bajo Cauca) .~Be reachable by phone throughout the study period. Being Duffy positive ( Fy +) . Levels of hemoglobin ( Hb) \> 11 g / dl. Availability to participate during the period in which they develop the study. Do not be participating in another clinical study~2. Preimmune group~Healthy men and women aged 18-45 years. Signing freely and voluntary informed consent , accompanied by two witnesses who also sign .~Having a history of infection (s ) and serological tests for malaria positive for P. vivax.~For women, use adequate contraception from the start restriction to be lifted by a doctor for contraception study .~Accept not to travel to areas considered endemic for malaria during Trophies infectious period (1 month ) ( Buenaventura , Tierralta , Pretoria , Tumaco Urabá and Bajo Cauca) .~Be reachable by phone throughout the study period. Availability to participate during the period in which they develop the study.~3. Voluntary blood donors~* Healthy men and women aged 18-45 years.~* Be positive diagnosis of P. vivax determined by thick smear examination .~* The patient must not have circulating malaria parasites such as P. falciparum or P. malariae .~* Have a parasitemia ≥ 0.1 %. by thick smear .~* Hb ≥ 9 g / dL at the time of diagnosis of malaria.~* The patient must have the capacity to provide informed consent freely and voluntarily . Should be illiterate may assert its decision to participate by putting their fingerprint in the format consent. Minors who are between 15 and 17 and wishing to participate must sign the informed consent and one of its Parents must sign the informed consent, accompanied by 2 witnesses who also sign~Exclusion Criteria:~* Step 1~  * Negative IFAT (\< 1:20) for P. vivax on screening tests~ * Other criteria used in the case of naive volunteers, except a history of having lived in an endemic area for the past 6 months.~Step 2 Patients that have chronic or acute disease, different from malaria by P. vivax.~Having a history of disease or clinical conditions that according to medical criteria might increase significantly the risk related with participation on this study Hemoglobin levels \<9 g/dL at the time of recruitment Have received antimalarial treatment before the diagnosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Experimental (Type: EXPERIMENTAL): 10 individuals per sub- group to be immunized with the Vaccine PvCS N+C at month 0 and the Vaccine PvCS N+C+R at months 2 and 6
- Control (Type: PLACEBO_COMPARATOR): six individuals for each sub- group to be immunized with placebo SSN Montanide ISA-51

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete